← Back to patent-cliff list
18F-LNC1007
Tier C — Watch / trade18F-LNC1007
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：ITGAV&ITGB3, FAP
Indications (approved)：Renal cell carcinoma, Solid tumour, Diagnostic agent, Neoplasm
Regional status
US
-
EU
-
China
Phase III
2025-12-11
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 18F-LNC1007?
Approved indications include: Renal cell carcinoma, Solid tumour, Diagnostic agent, Neoplasm.
When does the 18F-LNC1007 patent expire?
No public expiry year is available for 18F-LNC1007 yet; this page updates once verified.
How do I get a quote for 18F-LNC1007 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29